Traitements actuels de la sclérose en plaques

1993, Interferon beta -1b is effective in relapsing –remitting multiple sclerosis. I. Clinical results of multicenter, randomized, double blind, placebo-controlled trial, Neurology, 43, 655, 10.1212/WNL.43.4.655 Jacobs, 1996, Intramuscular interferon-beta-1a for disease progression in relapsing multiple sclerosis, Ann N Eurol, 39, 285, 10.1002/ana.410390304 1998, Randomised double- blind placebo controlled study of interferon beta 1a in relapsing remitting multiple sclerosis, Lancet, 352, 1498, 10.1016/S0140-6736(98)03334-0 Johnson, 1995, Copolymer1 reduces relapses rate and improves disability in relapsing remitting multiple sclerosis: result of phase III multicenter, double blind, placebo-controlled trial, Neurology, 45, 1268, 10.1212/WNL.45.7.1268 Edan, 1997, Therapetic effect of Mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomized multicenter study of active disease using MRI and clinical criteria, JNNP, 62, 112 Polman, 2006, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, 354, 899, 10.1056/NEJMoa044397 Wolansky, 2007, Betaferon versus Copaxone in MS with triple –dose gadolinium and 3-T MRI endpoints (BECOME) announcement of final primary outcome, Mult Scler, 13, 206 Mikol, 2007, Regard Trial: a randomized assessor - blinded trial comparing INF beat 1a and glatiramer acetate in RR MS, Mult Scler, 13, 119 Jacobs, 2000, Intramuscular interferon beta 1a therapy initiated during a first demyelinating event in multiple sclerosis, N Engl J Med., 343, 898, 10.1056/NEJM200009283431301 Kappos, 2006, Treatment with interferon beat 1b delays conversion on to clinically definite and Mac Donald MS in patients with clinically isolated syndromes, Neurology, 67, 1242, 10.1212/01.wnl.0000237641.33768.8d Comi, 2008, For PreCISe study group. Treatment with glatiramer acetate delays conversion to clinical definite multiple sclerosis in patients with CIS: subgroup analyses, Mult Scler, 14, S38 Goodkin, 2000, Interferon-beta-1b in secondary progressive MS: Clinical and MRI Results of a 3 year randomized controlled trial, Neurology, 54, 2352 SPECTRIMS Study Group Hughes RAC, 2001, Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results, Neurology, 56, 1496, 10.1212/WNL.56.11.1496 Polman, 2006, A randomized, placebo- controlled Trial of Natalizumab for relapsing multiple sclerosis, N Engl J, 354, 899, 10.1056/NEJMoa044397 Yousry, 2006, Evaluation for progressive multifocal leuko-encephalopathy in patients treated with natalizumab, N Engl J Med, 355, 924, 10.1056/NEJMoa054693 Faulds D, Balfour JA, Chrisp P, Langtry HD. Mitoxantrone a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer. Drugs, 41: 400-49. Watson, 1991, Suppression of demyeliation by mitoxantrone, Int J Imunopharmac, 923, 10.1016/0192-0561(91)90045-9 Le Page, 2006, Étude observationnelle de la mitoxantrone dans les formes rémittentes actives de la SEP suivis à long terme d’une cohorte de 100 patients consécutifs, Rev Neurol (Paris), 162, 185, 10.1016/S0035-3787(06)74998-0 Hartung, 2002, Mitoxantrone in progressive multiple sclerosis: a placebo-controlled double blind, randomized, multicenter trial, Lancet, 360, 2018, 10.1016/S0140-6736(02)12023-X Ghalie, 2002, Cardiac adverse effects associated with Mitoxantrone therapy in patients with MS, Neurology, 59, 909, 10.1212/WNL.59.6.909 Beck, 1992, A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The optic Neuritis Study Group, N Engl J Med, 326, 581, 10.1056/NEJM199202273260901 2001, Conférence de consensus sur la SEP, Rev Neurol, 157, 1184 Lubetzki, 2006, Perspectives thérapeutiques dans la SEP, Rev Prat, 56, 1347 Lubetzki, 2005, Promoting repair in multiple sclerosis: problems and prospects, Curr Opin Neurol, 18, 237, 10.1097/01.wco.0000169739.83793.e0